Praetego Inc., a Durham-based developmental stage drug company, has raised $250,000 by selling debt.

The company filed the Form D on Thursday. The filing did not disclose how the company intends to use the money.

Praetego was founded in 2017 and primarily focuses on preventing and treating the effects of acute and chronic oxidative stress, which could help prevent chronic illnesses like cancer, heart failure and depression.

Praetego’s lead candidate is a drug that protects against the risk of acute kidney injury in a surgical population.

Pepper Landson is the CEO and cofounder of Praetego. She holds a degree in life sciences from Marymount University.

Landson previously worked with the U.S. military medical system in the funding and conduct of clinical research and served as CEO of Linked Urology Research Network.

Companies relying on a Reg D exemption do not have to register their offering of securities with the SEC, but they must file what’s known as a Form D electronically with the SEC after they first sell their securities.

The form can be found here.